NCT04407091View on ClinicalTrials.gov

A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

August 6, 2020

Study Completion Date

August 6, 2020

Conditions
Cardiovascular Disease
Interventions
DRUG

14C]AZD4831 Oral Solution

10 mg dose of \[14C\]AZD4831 Oral Solution

Trial Locations (1)

NG11 6JS

Research Site, Ruddington

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

AstraZeneca

INDUSTRY